Finally, we recognized three prospective novel markers of CRC progression (CEA, IL-8 and prolactin) that hold potential to be utilised in clinical oncology, as they significantly increase with CRC progression and correlate with Dukes’ stage. This evidence concerns the gene PRL and colorectal carcinoma.